Part II: FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting

FDA is formally reviewing BPC-157, TB-500, MOTS-c, Semax, and 3 other gray market peptides at its July 2026 advisory committee meeting. The wellness clinic industry is watching closely.

These 7 peptides have no USP monographs, no FDA-approved drug status, and no path to legal 503A compounding until FDA acts. Most were previously in a do-not-compound cate…